Cargando…
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336556/ https://www.ncbi.nlm.nih.gov/pubmed/28154372 http://dx.doi.org/10.1038/emm.2016.143 |
_version_ | 1782512217754697728 |
---|---|
author | Lopez-Millan, Belen Diaz de la Guardia, Rafael Roca-Ho, Heleia García-Herrero, Carmen M Lavoie, Jessie R Rosu-Myles, Michael Gonzalez-Rey, Elena O'Valle, Francisco Criado, Gabriel Delgado, Mario Menendez, Pablo |
author_facet | Lopez-Millan, Belen Diaz de la Guardia, Rafael Roca-Ho, Heleia García-Herrero, Carmen M Lavoie, Jessie R Rosu-Myles, Michael Gonzalez-Rey, Elena O'Valle, Francisco Criado, Gabriel Delgado, Mario Menendez, Pablo |
author_sort | Lopez-Millan, Belen |
collection | PubMed |
description | Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases. |
format | Online Article Text |
id | pubmed-5336556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53365562017-03-24 Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease Lopez-Millan, Belen Diaz de la Guardia, Rafael Roca-Ho, Heleia García-Herrero, Carmen M Lavoie, Jessie R Rosu-Myles, Michael Gonzalez-Rey, Elena O'Valle, Francisco Criado, Gabriel Delgado, Mario Menendez, Pablo Exp Mol Med Original Article Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases. Nature Publishing Group 2017-02 2017-02-03 /pmc/articles/PMC5336556/ /pubmed/28154372 http://dx.doi.org/10.1038/emm.2016.143 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Article Lopez-Millan, Belen Diaz de la Guardia, Rafael Roca-Ho, Heleia García-Herrero, Carmen M Lavoie, Jessie R Rosu-Myles, Michael Gonzalez-Rey, Elena O'Valle, Francisco Criado, Gabriel Delgado, Mario Menendez, Pablo Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
title | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
title_full | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
title_fullStr | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
title_full_unstemmed | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
title_short | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
title_sort | therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336556/ https://www.ncbi.nlm.nih.gov/pubmed/28154372 http://dx.doi.org/10.1038/emm.2016.143 |
work_keys_str_mv | AT lopezmillanbelen therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT diazdelaguardiarafael therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT rocahoheleia therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT garciaherrerocarmenm therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT lavoiejessier therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT rosumylesmichael therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT gonzalezreyelena therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT ovallefrancisco therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT criadogabriel therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT delgadomario therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease AT menendezpablo therapeuticeffectoftheimmunomodulatorydruglenalidomidebutnotpomalidomideinexperimentalmodelsofrheumatoidarthritisandinflammatoryboweldisease |